社区老年人阿尔茨海默病血液标志物与脑结构改变模式
该研究纳入361名来自瑞典人群队列的无痴呆老年人(MMSE≥27且无既往脑血管事件),检测基线血p-tau217、NfL与GFAP,并在基线和3年和/或6年后进行脑MRI,用线性混合模型分析标志物与脑体积及脑白质高信号变化的关系。结果显示,p-tau217升高与海马和杏仁核萎缩更快相关,GFAP与全脑组织体积下降、脑室扩大和海马萎缩相关,NfL则与更广泛的萎缩及WMH累积加速相关。
要点
- 血p-tau217升高提示海马和杏仁核等AD相关区域萎缩更快。
- GFAP升高与全脑组织体积下降、脑室扩大和海马萎缩相关。
- NfL升高与广泛萎缩及脑白质高信号累积加速相关。
核心结论
- 在认知未受损的社区老年人中,AD相关血液标志物可能已能反映不同模式的结构性脑改变。
研究设计与样本
- 瑞典人群为基础的队列研究,纳入361名无痴呆、MMSE≥27且无既往脑血管事件的参与者,基线与3年和/或6年随访脑MRI,采用线性混合模型分析。
主要发现
- p-tau217较高与海马体积下降更快(β*year=-0.047,95%CI=-0.077至-0.018)及杏仁核体积下降更快(β*year=-0.064,95%CI=-0.105至-0.022)相关。
- GFAP升高与全脑组织体积下降更快(β*year=-0.040,95%CI=-0.059至-0.021)、脑室扩大(β*year=0.028,95%CI=0.013至0.042)及海马萎缩(β*year=-0.038,95%CI=-0.064至-0.013)相关。
- NfL较高者全脑组织体积下降更陡、脑室扩大、海马和杏仁核萎缩及WMH累积更快;排除基线轻度认知障碍者后结果基本一致。
临床怎么用
- 对社区认知正常老年人,可结合血p-tau217、GFAP和NfL评估不同模式的脑结构变化风险,辅助早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate the associations between Alzheimer's disease (AD)-related blood biomarkers and changes in brain volumes and cerebrovascular burden in community-dwelling older adults. METHODS: We included 361 dementia-free participants with a Mini-Mental State Examination (MMSE) score ≥ 27 and without prior cerebrovascular events from a Swedish population-based study. Blood phosphorylated-tau217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured at baseline. Brain magnetic resonance imaging (MRI) was performed at baseline and after 3 and/or 6 years. Linear mixed models were used to examine associations between AD-related blood biomarkers and changes in volumes of total brain tissue (TBTV), lateral ventricles, hippocampus, amygdala, and white matter hyperintensities (WMHs). RESULTS: During the follow-up, higher p-tau217 was associated with faster volume loss in the hippocampus (β*year = -0.047, 95% confidence interval [CI] = -0.077 to -0.018) and in the amygdala (β*year = -0.064, 95% CI = -0.105 to -0.022). Elevated GFAP was linked to faster TBTV decline (β*year = -0.040, 95% CI = -0.059 to -0.021), ventricular enlargement (β*year = 0.028, 95% CI = 0.013 to 0.042), and hippocampal shrinkage (β*year = -0.038, 95% CI = -0.064 to -0.013). Participants with higher NfL showed steeper TBTV decline, ventricular enlargement, hippocampal and amygdala shrinkage, and faster WMH accumulation. Results remained largely consistent after excluding participants with mild cognitive impairment at baseline. INTERPRETATION: In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation. These findings suggest that AD-related blood biomarkers may capture different dementia-related structural brain changes already at early stages. ANN NEUROL 2026;100:987-997.
引用
- Valletta M, Vetrano DL, Laukka EJ, et al. Blood Biomarkers of Alzheimer's Disease and Patterns of Structural Brain Changes in the Community. Ann Neurol. 2026. PMID: 42515850. doi:10.1002/ana.78309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。